powered by delhi times, aurangabad times, maharashtra times
.
.consider making a donation to support the coverage that shapes the face of berkeley.
.
-
.
submit a letter to the editor
-
.
- eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention. .
biohaven: "rimegepant pivotal phase 3 trial results -- conference call." .
.
http://lm360.us/Yenor-grandma-of-Lion-from-Pareklisha?Romarsist=116
.
.submit a letter to the editor